I don’t know where else you would find an investment bank with such expertise. They could move from financial and strategic discussions to highly scientific, clinical discussions with ease. In the end, they brought all these perspectives to bear, developing an exceptional strategy that created value for our company.
Outcome Capital has demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space. They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.
They understood our technology and business as well as anyone.
Outcome worked diligently with our executives and board to develop and communicate a strategy that was instrumental in enhancing the value of our company. Their business acumen and knowledge of our market space drove a complex transaction to a very successful close.
Advanced Uro-Solutions engaged the services of Outcome Capital late in the process of being acquired. Outcome Capital took control of all further negotiations and masterfully increased the value of our final offering. The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner. Arnie and Oded brought an amazing team of talented, organized and highly effective individuals. We could NOT have been more satisfied.
With the assistance of Outcome’s recognized expertise in the biomedical field, GenePOC was able to devise and communicate a market-aligned strategy leading to the completion a transaction efficiently and effectively. We are very pleased with the way Outcome supported us throughout this process.
From advances in personalized medicine and diagnostics to transformations in medical devices and digital health — not only are avenues of patient care changing but also the financial landscape and fluid interplay between life science sectors. The Outcome Capital Life Sciences team is dedicated to following the most recent scientific advancements as well as understanding their implications on market dynamics. The unmatched combination of scientific backgrounds and business acumen of Outcome professionals ensures they see the value of their clients’ businesses not only in today’s market but also the future potential enabling them to maximize value for their clients. Outcome Capital is a trusted partner to middle-market companies providing M&A, capital raise and advisory services in life science markets.
Dr. Ben-Joseph is Managing Director with Outcome Capital and co-lead of its life sciences and healthcare practice. He brings a unique combination of executive, entrepreneurial, scientific and transactional experience to Outcome Capital and is passionate about assisting cutting-edge life sciences companies in enhancing their strategic value and developing a path to successful liquidity.
Dr. Ben-Joseph also serves on the Board of Directors of life sciences companies: XableCath, a clinical stage medical device innovator developing cost-effective treatment options for peripheral and cardiovascular disease, KidneyCure, a regenerative medicine company developing novel cell-based therapies for the treatment of chronic renal disease and ELT Sight, a clinical stage ExTra Laser trabeculotomy for the treatment of glaucoma.. Before joining Outcome Capital, Dr. Ben-Joseph was Managing Director at Boston Equity Advisors, a boutique investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector. Prior to that, Dr. Ben-Joseph was an Executive-in-Residence at Oxford Bioscience Partners, a life sciences venture capital firm, and CEO and co-founder of Caliber Therapeutics, a company engaged in the development of catheter-based drug delivery products for the intervention of atherosclerotic diseases. His past managerial and entrepreneurial positions also include President and CEO at Deep Vein Medical, an early stage medtech company dedicated to treating deep venous reflux in patients suffering from chronic venous insufficiency, President and CEO of X-Cell Medical, a clinical stage drug/device convergence company engaged in the development of novel stent-based anti-restenotic drugs, President of Ester Neurosciences, a clinical stage biotech company engaged in the development of novel compounds for the treatment of neurological diseases, and co-founder and CEO of Biolight Phototherapy, a company engaged in the development of laser-based medical devices for the treatment of dermatological disorders and allergies.
His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, a Visiting Associate Professor at Tokushima University in Japan and a Visiting Scientist at Parke-Davis (Pfizer). Dr. Ben-Joseph has published numerous peer-review scientific papers as well as industry publications and has received numerous awards and scholarships.
Dr. Ben-Joseph graduated with Honors from Imperial College London and received his Ph.D. from the University of Cambridge. He completed his post-doctoral training at the University of Michigan and received an MBA magna cum laude from the University of Bradford. He is a FINRA Registered Securities Representative holding Series 7, 63 and 79 and a Registered Securities Principal holding a Series 24.
Arnie Freedman is a Managing Director with Outcome Capital, and co-lead of its healthcare practice. He also serve on the Board of Director of Transonic Imaging, a clinical stage company developing a novel imaging modality for the screening and diagnosis of breast cancer. Mr. Freedman has extensive experience in private equity financing, mergers and acquisitions and preferred securities. His primary focus is in life sciences offerings, including medical devices, diagnostics and drug development. He assists companies with pre-IPO and early stage financing and prepares companies for the rigor required for merger and acquisition activity.
Mr. Freedman has been involved in the management of entrepreneurial businesses for over 25 years, previously as a co-founder and principal in Boston Equity Advisors, LLC, a registered broker-dealer and boutique investment-banking firm. In this company, Mr. Freedman focused on M&A transactions, private placements of debt and equity with institutional investors from the venture capital, private equity, family-foundation and hedge fund community. He uses his knowledge of the private placement process to help clients prepare for the scrutiny of potential investors by conducting a pre-financing review of client operations and corporate structure, recommending changes, assisting management in implementing those changes and preparing documentation investors require including business plans, marketing and insurance reimbursement strategies and financial models. Arnie brings his operating expertise to bear on the advice and counsel he provides to his clients.
Prior to Boston Equity Advisors, Mr. Freedman was the founder and CEO of Rustel, a Russian/American satellite telecommunications company, where he developed an extensive connection to the European investment community. He worked closely and collaborated with investment banking advisors Deutsche Morgan Grenfell, Salomon Brothers, and Creditanstalt International Advisors.
Mr. Freedman is a graduate with honors from the University of Massachusetts. He is a FINRA Registered Securities Representative holding a Series 7, 63 and 79 and a Registered Securities Principal, Series 24.
Dr. Ellen Baron brings extensive experience in the private placement of securities for life science companies with deep domain expertise across multiple disciplines in pharmaceutical and biotechnology industries. Ellen is committed to the success of emerging growth companies bringing nearly 30 years of industry experience with proven deal execution and a unique access to the people, resources and markets that are vital for success. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech.
Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a Boston-based biotech pioneering antibodies to ion channels, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company.
Dr. Baron was most recently a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Prior to that she spent 9 years as Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies.
Ellen previously served as Senior Vice President, Business Development at Human Genome Sciences, a publically traded biopharmaceutical company where she was responsible for all business functions of the Company including corporate partnering, licensing and investor interface.
Ellen previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. She has over 30 years of operating and investment expertise across the spectrum of the pharmaceutical and biotechnology industries, with particular emphasis in oncology, neurology, and infectious disease. Ellen holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate at the Public Health Research Institute in New York.
Craig is the Vice President of Life Sciences at Outcome Capital and brings corporate and commercial expertise in the diagnostic and life science space. A business leader with extensive global experience in the life sciences and healthcare industries, Craig has held various executive positions from start-up companies through large, well-established international corporations. His success building commercially viable and sustainable enterprises has lead to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. In addition to his role as Vice President of Life Sciences at Outcome Capital, Craig also volunteers with mentoring activities for Women in Biotech and as an Advisor to Springboard Enterprises.
Craig’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations. His key successes include developing and launching new businesses at Fisher Healthcare, HandyLab, Becton Dickinson and Caliper Life Sciences within the diagnostic market space. Craig’s knowledge of the diagnostic and life science tools markets has allowed him to develop markets across the globe and leverage strategic partnerships to further market expansion for many of his clients.
Craig holds a Bachelor of Science from the University of Wisconsin – Madison and a Master of Science from Yale University. He is a FINRA Registered Securities Representative holding Series 79 and 63.
Thomas Busby is a Senior Associate and has been with Outcome Capital since 2015. He focuses on medical technology, digital health and life science services segments with particular interest in innovative life science companies that deliver patient impact by leveraging novel approaches. Thomas is driven by the desire to identify disruptive technologies and services that require unique strategic thought and assistance to realize their full market potential. Thomas has been published in leading life science journals Life Science Leader and The Pharma Letter, and also serves on the board of HealthTech Build, a Boston-based digital health innovation group.
Prior to his career in life-science investment banking, Thomas pursued his passion for the public service and non-profit sectors working in a variety of leadership and management positions, and at one time held a Massachusetts teaching license.
Thomas completed his MBA at Suffolk University’s Sawyer Business School on full academic scholarship where he was President of the school’s Graduate Business Association and class speaker at graduation. Prior, he completed a BS in Philosophy with Honors from Suffolk’s College of Arts & Sciences. Committed to giving back, Thomas is currently the President of the College of Arts & Sciences Alumni Board of Directors. Thomas is a FINRA Registered Securities Representative holding his Series 79 and 63.
Dr. Echoe Bouta joined Outcome Capital in October 2017 as a Senior Analyst. Echoe completed her PhD at the University of Rochester in biomedical engineering, followed by a Research Fellow position at Massachusetts General Hospital and Harvard Medical School. Her research focused on understanding the role of the lymphatic system in multiple disease states, and determining the therapeutic potential of targeting lymphatics. She has authored numerous peer-reviewed publications, and received multiple fellowships in support of her prior research. While at Mass General, she served as Vice Chair of the Mass General Post-doc Association, and Chair of the Industry Career Exposure Club, organizations which she continues to support as an alumni.
Dr. Bouta is a FINRA Registered Securities Representative holding her Series 79. She resides in Cambridge, MA.
Dr. Nick Frame joined Outcome Capital in July of 2019 as an Analyst. His primary interests are in leveraging his technical and scientific knowledge to advise life science companies in moving inventions from benchtop testing to impacting clinical outcomes. Nick graduated with a B.A. in Biophysics and minor in Entrepreneurship and Management from Johns Hopkins University and completed his PhD in Biophysics at Boston University School of Medicine. His graduate research focused on understanding the structure-function relationship of specific proteins to understand both normal and disease states, specifically cardiovascular and amyloid diseases. He has published multiple first-author research manuscripts and received a pre-doctoral training grant to study cardiovascular disease. Nick has extensive knowledge in biochemical and biophysical techniques and assay development and previously worked developing an automated thermodynamic assay for characterization of biologics and formulations.
While at BU, Nick was an active member of Tufts Advisory Partners, which works with early-stage life science companies, and participated in the Innovate@BU workshops. In addition, Nick acted as a mentor for incoming PhD students at Boston University and a teaching assistant in several first-year graduate courses.
Dr. Manning serves as a Senior Advisor with Outcome Capital’s biotechnology practice and manages its UK operations. He brings significant experience of the UK and European Capital markets, strong relationships within the European Life Science industry, entrepreneurial flair and a strong academic background to Outcome Capital. He is committed to enhancing the corporate and shareholder value of innovative life science companies.
Before joining Outcome Capital, Dr. Manning accrued over 25 years of international Life Sciences experience, including over 3 years as Founder and Managing Director of strategic and financial advisory firm, Akesios Associates. Shawn also spent over 12 years as a rated Equity Analyst with Dresdner Kleinwort Benson, SG-Cowen, Société Generale, and Singer Capital Markets, covering ‘Big Pharma’, speciality and emerging pharmaceutical, and biotechnology. Since 2005 Manning’s research supported over £500 million in new funding for Life Science companies. Before entering the City of London, Manning spent 5 years consulting to the pharmaceutical industry, and managing Datamonitor’s Healthcare practice. In this capacity he also worked alongside European, US and Japanese pharmaceutical companies, leading consultancy projects focusing primarily on strategic product positioning, including portfolio, opportunity and pricing analysis.
Manning holds a Doctorate degree from the University of Oxford (Hertford College), specialising in infectious disease and a BSc (Hons) and ARCS from Imperial College, London. He is a Fellow of the Royal Society of Medicine, a member of the Advisory Board for OBN, the UK’s largest Life Sciences industry network, and Chairman of OBN’s investment and tax Special Interest Group (itSIG).
Dr. Cohen is an accomplished biologist bringing significant drug discovery and development expertise to Outcome Capital, leveraging her academic, pharmaceutical and biotech experience.
In 2017, Dr. Cohen co-founded The RNA Medicine Company and served as the Company’s Chief Scientific Officer (CSO) until 2019. Currently, she remains the scientific advisor of the company. The RNA Medicine Company focuses on identifying small molecules targeting the biogenesis of oncogenic microRNAs. Between 2006 and 2017, Dr. Cohen served as CSO at Beryllium, a specialized target-based protein structure and characterization CRO (acquired by UCB Pharma), Asterand, a global supplier of human tissue and tissue-based research services and Rosetta Genomics, a microRNA-based diagnostic company. During her tenure at Rosetta, three diagnostic tests based on microRNA for differential diagnostics of tumors were developed.
Dr. Cohen also held several executive positions at Novartis, including Vice President and Global Head of Functional Genomics. While at Novartis, Dr. Cohen initiated the Histone Deacetylase Inhibitor program. One of the inhibitors was approved by the FDA for the treatment of Multiple Myeloma. Prior to Novartis, Dr Cohen was an adjunct professor at the UMDNJ-Robert Wood Johnson Medical School.
Dalia is currently a member of the scientific advisory boards of the Massachusetts Life Sciences Center. She holds a Bachelor of Sciences in biology, a Master’s degree in virology and a Doctorate in cell biology from the Israel Institute of Technology. She completed her postdoctoral training at the Albert Einstein College of Medicine.
Dr. Popper serves as Senior Advisor in Outcome Capital molecular diagnostics and biotechnology practices. She brings significant expertise and track record in positioning novel technologies toward successful implementation and commercialization. Dr. Popper is also the Co-Founder and President of Popper and Company, a specialty consulting firm focused in diagnostics, information-generating tools and healthcare analytics, where she and her team leverage their extensive knowledge of the trends and forces shaping the life sciences industry and its participants.
Dr. Popper has more than 25 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings – and extensive track record creating strategic and business partnerships in the biotech arena – is key to the insights she provides to her clients.
During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Subsequently, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe.
Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins. Dr. Popper is and Advisory Board member of the Bloomberg Johns Hopkins School and Public Health and inHealth, the Hopkins Precision Medicine Initiative. She is a board member of Diversigen (a microbiome-based company) and LBT Innovations (an Australian AI-based lab automation company).
Chuck Morrison serves as a Senior Advisor at Outcome Capital’s diagnostics and biotechnology practices. He brings significant expertise and a track record in successfully structuring, negotiating and executing acquisitions, licensing, partnerships, and distribution transactions. Chuck is a business development executive with over thirty years of life science, biotechnology and diagnostic expertise, including 13 years of corporate business development. He is a leader in the life science sector with proven business acumen, international experience, integrity, strategic vision and focus on execution. Known for driving results and overcoming difficult challenges.
Chuck is currently a non-executive Board Member for GenePOC, Inc., a molecular diagnostic company developing point-of-care platforms for the rapid detection of infectious diseases (recently acquired by Meridian Bioscience). He is also Head of Business Development at Proteomics International, Perth, Australia. PI has developed a proprietary mass spectrometry biomarker discovery platform and has recently discovered biomarkers for the diagnosis of diabetic kidney disease. Previously, Chuck held various managerial positions at PerkinElmer, NEN Life Sciences and DuPont Medical Products.
Chuck is currently providing strategic consulting services to early-stage and smaller biotech companies, positioning toward merger & acquisitions, partnerships, licensing and joint ventures, as well as team building, product commercialization and carving out a path to commercialization.
Dr. Don Haut brings a broad life-science business perspective to Outcome Capital from senior executive and Board positions in Strategy, M&A, and General Management, with deep domain expertise across multiple disciplines in pharmaceutical, biotech, and medical device industries. Don is an experienced transaction professional with over $4B in deals to his credit.
Dr. Haut is the Chief Business Officer a Sherlock Bioscience, a molecular diagnostics company. He currently serves on the Board of Directors for three health care companies: MiMecore Therapeutics, Arthrosurface, and Xiros. Prior, he was Chief Business Officer at Histogenics Corporation and Vice President for New Business Ventures at The Medicines Company, where he was responsible for leading that company’s deal to license Alnylam’s PCSK9 inhibitor. Previously, he was the Senior Vice President for Strategy and Business Development at Smith and Nephew’s Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities, and also built and ran Smith & Nephew’s Women’s Health business. Dr. Haut also previously held similar roles at 3M, JSB Partners and McKinsey and Company.
Don obtained his MBA at Washington University’s Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.
Dr. Lauterbach serves as a Senior Advisor within the life sciences team at Outcome Capital. He has practiced vascular and endovascular surgery since completing his fellowship training at Massachusetts General Hospital and Harvard Medical School in 2001, including in-depth experience with many of the minimally invasive technologies available in the peripheral vascular space.
Dr. Lauterbach is currently the Medical Director for Xablecath, Inc., a device company in Salt Lake City, Utah. He has facilitated the companies receipt of FDA clearance for their devices and heads the clinical evaluation phase of their products in the EU and USA. The potential for Xablecath to facilitate lower extremity revascularization and limb salvage in a simple, safe, and effective manner is exciting and resonates with Lauterbach’s commitment to limb salvage as a vascular surgeon. He has been able to engage in the industrial side of his specialty and is comfortable discussing medical technology and clinical outcomes with regulators, businesspeople, engineers, and other clinicians in a cogent manner.
Dr. Lauterbach has a robust scientific background and participated in independent basic science research beginning as an undergraduate at Middlebury College continuing through his clinical practice at Cedars-Sinai Hospital in Los Angeles in which he was the primary investigator for a phase III multi-center national trial of a genetic modification treatment for vein grafts used for lower extremity arterial bypass.
Dr. Lauterbach’s scientific interests, familiarity with novel technology, and desire for improved patient outcomes drives his desire to engage with Outcome Capital. He enjoys being a member of multidisciplinary teams who share the common goal of driving innovation to the patient.
Tuesday, July 23 6:00-7:30pm Cost: This event is hosted by Dr. Oded Ben-Joseph (Darwin 1988), Managing Director, Outcome Capital, LLC, and is free to attend with prior RSVP. Outcome Capital, LLC 99 High Street, Suite 2900 Boston, MA RSVP to Megan Cokely at firstname.lastname@example.org Cambridge in America’s Boston Regional Committee invites you to another exclusive event for […]Read More
Outcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has secured growth capital from State Farm Ventures and Ferguson Ventures along with […]Read More